Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. The company engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company offers its products for various therapeutic categories, such as anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastrointestinal, gynaecological, hormones, neuro/Cns, ophthal/otological, and other areas, as well as pain and analgesics, respiratory, and vitamins, minerals, and nutrients; and contract development services. The company was incorporated in 1978 and is headquartered in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.

Revenue projections:

Revenue projections for GLAND
Revenue projections for GLAND

Revenues for GLAND are expected to drop compared to the previous year, which could be a cause for concern for investors. A decline in earnings may negatively impact the company's profitability, leading cautious investors to reconsider their positions, as it often signals challenges in overall financial health.

Financial Ratios:

currentRatio 0.00000
forwardPE 26.39763
debtToEquity 3.42800
earningsGrowth 0.49800
revenueGrowth 0.07400
grossMargins 0.57728
operatingMargins 0.17714
trailingEps 42.44000
forwardEps 65.01000

GLAND's Forward PE being in a good range indicates the stock is priced well relative to its earnings. It is not overvalued, leaving space for future growth, making it an appealing option for investors interested in long-term value appreciation.
GLAND's forward EPS being higher than its trailing EPS signals anticipated growth in profitability for the current financial year. This suggests that GLAND is on track to improve its earnings, outpacing the previous year's performance and reflecting positive market expectations.

Price projections:

Price projections for GLAND
Price projections for GLAND

GLAND's price has consistently hovered around the lower limit of price projections. This pattern suggests that the stock may be underperforming relative to expectations, which could lead to concerns among investors.

Insider Transactions:

Insider Transactions for GLAND
Insider Transactions for GLAND


7 Gland Pharma Limited shares were sold in recent transactions, with market price at 1837.9357212611608.There were no sell transactions recorded during the period under consideration.More recent purchases than sales at current price levels for GLAND could signal growing investor confidence. This buying trend might suggest that market sentiment is leaning toward a positive outlook for the stock, possibly indicating expectations of favorable performance in the near future.

Recommendation changes over time:

Recommendations trend for GLAND
Recommendations trend for GLAND


The recent buy bias for GLAND from analysts signals strong confidence in the stock's potential. This positive sentiment could encourage investors to see GLAND as a smart place to invest their money, especially those looking for stable, long-term returns in a well-established company.